Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Selective Elimination of Autoreactive B Cells Using Multivalent Polyisocyanopeptide-Based Antigen-Toxin Conjugates.

Biomacromolecules·2026
Same author

A clinical protocol for the detection of comorbidities associated with monogenic causes of male infertility.

Human reproduction (Oxford, England)·2026
Same author

MitoTam induces ferroptosis and increases radiosensitivity in head and neck cancer cells.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2024
Same author

Radiotherapy induces an increase in serum antioxidant capacity reflecting tumor response.

Clinical and translational radiation oncology·2024
Same author

Tamoxifen induces radioresistance through NRF2-mediated metabolic reprogramming in breast cancer.

Cancer & metabolism·2023
Same author

Sialic acid blockade in dendritic cells enhances CD8<sup>+</sup> T cell responses by facilitating high-avidity interactions.

Cellular and molecular life sciences : CMLS·2022
Same journal

Intracranially injected chimeric antigen receptor T cells eradicate glioblastoma cells but have limited potential to persist in the brain in a syngeneic mouse model.

Cancer immunology, immunotherapy : CII·2026
Same journal

Real-world treatment patterns and early outcomes in advanced intrahepatic cholangiocarcinoma: a descriptive case series.

Cancer immunology, immunotherapy : CII·2026
Same journal

CXCL13-CXCR5 signaling in CD8<sup>+</sup> T cell recruitment and lymphoid immune organization in clear cell renal cell carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Conserved minimal CD8 cytotoxic immune-state unit in an IL18R1-associated immune program in hepatocellular carcinoma.

Cancer immunology, immunotherapy : CII·2026
Same journal

Safety and feasibility of 5T4 antibody-coupled allogeneic NK cell therapy for solid tumors: a first-in-human phase 1 trial.

Cancer immunology, immunotherapy : CII·2026
Same journal

Time-dependent cytokine landscapes in an ex vivo microfluidic glioblastoma platform.

Cancer immunology, immunotherapy : CII·2026
See all related articles

Related Experiment Video

Updated: Jun 28, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Targets for active immunotherapy against pediatric solid tumors.

J F M Jacobs1, P G Coulie, C G Figdor

  • 1Department of Pediatric Hemato-oncology, Radboud University Medical Centre Nijmegen, Nijmegen, The Netherlands. H.Jacobs@cukz.umcn.nl

Cancer Immunology, Immunotherapy : CII
|November 15, 2008
PubMed
Summary
This summary is machine-generated.

Cancer immunotherapy shows promise, but pediatric patients need more tumor-specific targets. Identifying these antigens is crucial for developing effective immunotherapies for children with solid tumors.

More Related Videos

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: Jun 28, 2026

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
12:42

Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo

Published on: January 7, 2019

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
12:55

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care

Published on: February 16, 2015

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

  • Immunology
  • Oncology
  • Pediatric Medicine

Background:

  • Antibodies and T lymphocytes show potential in cancer eradication across models and trials.
  • Cancer immunotherapy strategies using tumor-specific T cells and antibodies have advanced.
  • Effective immunotherapy relies on identifying suitable tumor-specific target antigens.

Purpose of the Study:

  • To review the current status of cancer immunotherapy in children.
  • To focus on the identification of tumor-specific antigens in pediatric solid tumors.
  • To address the paucity of identified tumor-specific antigens in pediatric cancers.

Main Methods:

  • Review of existing literature on cancer immunotherapy.
  • Analysis of studies on tumor-specific antigen expression in adult and pediatric tumors.
  • Discussion of challenges and opportunities in pediatric cancer immunotherapy.

Main Results:

  • Pediatric patients are ideal candidates for immunotherapy due to their robust immune systems.
  • Limited identification of tumor-specific antigens on pediatric tumors hinders treatment progress.
  • Significant research exists for adult tumor antigens, but less for pediatric ones.

Conclusions:

  • Pediatric cancer immunotherapy is underdeveloped compared to adult treatments.
  • Identifying novel tumor-specific antigens is critical for advancing pediatric cancer immunotherapy.
  • Further research into pediatric tumor antigens will improve treatment outcomes for children.